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91. ABSTRACT
Introduction: Hypercholesterolemia is an important risk factor for atherosclerosis and
cardiovascular disease (CVD), and serum LDL cholesterol is the primary goal of lipid-
lowering therapy. However, even subjects with low LDL and total cholesterol
concentrations have atherosclerosis. Other dyslipidemias, such as low HDL cholesterol
concentration, hypertriglyceridemia, and preponderance of small dense LDL particles,
have also the potential to promote atherosclerosis. The present studies were undertaken
to investigate 1) metabolic factors which may regulate LDL particle size, and 2)
possible associations between LDL particle size and atherosclerosis.
Subjects and methods: The study populations consisted of subjects with type 2
diabetes (three studies), subjects with familial combined hyperlipidemia (one study),
and healthy men (one study). LDL peak particle diameter (LDL size) was measured by
nondenaturing linear gradient gel electrophoresis. Vascular endothelial function was
measured as forearm blood flow response to intra-arterial infusion of endothelium-
dependent vasodilator acetylcholine. Blunted response to acetylcholine was considered
as an early sign of atherosclerosis. Progression of coronary artery atherosclerosis was
measured by changes in angiograms taken at least three years apart.
Results: Serum triglyceride concentration was strongly and inversely associated with
LDL size in all five studies. In addition to serum triglycerides, cholesteryl ester transfer
protein and hepatic lipase activities also modulated LDL size in subjects with familial
combined hyperlipidemia. Treatment of hyperglycemia with insulinotropic agents
nateglinide and glibenclamide in subjects with type 2 diabetes decreased postprandial
glycemia but did not influence fasting or postprandial plasma triglyceride
concentrations or LDL size. Treatment of type 2 diabetic subjects with fenofibrate
predictably decreased plasma triglyceride, total and LDL cholesterol and apolipoprotein
B concentrations. The decrease in plasma triglyceride concentration was associated with
an increase in LDL size. Small LDL size was significantly associated with impaired
endothelial function in healthy men and in men with type 2 diabetes. Moreover, small
LDL size was associated with increased progression of coronary atherosclerosis and it
augmented the atherogenic effect of high LDL cholesterol and apolipoprotein B
concentrations in patients with type 2 diabetes.
Conclusions: Small LDL size is associated with impaired endothelium-dependent
vasodilation and progression of coronary artery disease. The results support the idea that
small LDL size increases the progression of atherosclerosis. Serum triglyceride
concentration is the most important metabolic determinant of LDL particle size.
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2. REVIEW OF THE LITERATURE
2.1. OVERVIEW ON LIPOPROTEIN METABOLISM
2.1.1 Lipoprotein heterogeneity
Plasma lipoproteins are heterogeneous particles. They can be separated by size, density,
lipid and apolipoprotein composition, metabolic function, and the site of origin. The
lipoproteins containing apolipoprotein B100 (apoB100), which are secreted by the liver,
account for the majority of serum lipids in the fasting state. They are traditionally
separated by density into very low density (VLDL, Sf 20 to 400), intermediate density
(IDL, Sf 12 to 20) and low density (LDL, Sf 0 to 12) lipoproteins. However, lipoprotein
particles within VLDL, IDL, and LDL fractions are heterogeneous and they can be
further subfractionated. The lipoprotein subclasses have distinct structural and
metabolic properties, which are discussed below. Under postprandial conditions
apolipoprotein B48 containing chylomicrons and their remnants also circulate in
plasma. They are derived from intestine and compete for the same catabolic pathways as
the apoB100-containing lipoproteins.
2.1.2 Metabolism of apoB100 lipoproteins (VLDL-IDL-LDL cascade)
Packard et al. (1-3) have proposed the concept of metabolic channelling in VLDL-IDL-
LDL delipidation cascade (Figure 1). According to their theory there are two parallel
delipidation pathways: one for the particles originally secreted as VLDL1, and the other
for the particles originally secreted as smaller lipoproteins, i.e. VLDL2, IDL and LDL.
Lipoproteins derived from VLDL1 have slower catabolic rate and longer residence time
in plasma. The number of apolipoprotein C-II molecules or the ratio of apoC-II and
apoC-III on VLDL may influence the different catabolic rate of these lipoproteins (see
below). The factors that regulate which lipoproteins are secreted from the liver are not
apoB100
Tg
VLDL1
VLDL2
IDL
LDL
LPL
HL
HL
VLDL2
LPL
HL
HL
IDL
Figure 1. Lipoproteins are assembled in the liver by addition of triglycerides (Tg) to
apoB100. Directly secreted VLDL2 particles are the precursors of LDL that are rapidly
removed from the circulation. Large, Tg-rich VLDL1 particles give rise to LDL particles
that have long residence time in the circulation. Modified from Packard & Shepherd
(1997).
LDL
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known in detail, but insulin is probably one important factor. Insulin suppresses the
production of VLDL1 but not VLDL2 apoB in healthy men (4), but in men with type 2
diabetes this action of insulin is defective (5). Intrahepatic availability of triglycerides
probably also influences the size of the particles that are secreted.
Lipolysis of VLDL particles is mainly mediated by lipoprotein lipase (LPL) in
capillaries of muscle and adipose tissue. LPL activity in vivo is regulated by
apolipoproteins on the surface of VLDL particles and polymorphisms of LPL gene.
Apolipoprotein C-II is an important co-factor, which increases LPL activity, while
apolipoprotein C-III has the opposing effect. As VLDL particles become smaller and
less triglyceride-rich hepatic lipase (HL) gradually becomes more important in
hydrolysis of triglycerides, and the conversion of IDL to LDL is mediated mainly by
HL. Removal of apoB100 lipoproteins occurs not only as the uptake of LDL and IDL
by LDL receptor, but also as removal of VLDL particles (1,3).
2.2 LOW DENSITY LIPOPROTEIN PARTICLE
2.2.1 Structure of LDL
Low density lipoproteins carry cholesterol from the liver to peripheral tissues. Studies
using negative staining electron microscopy implied that LDL particles are spherical
with a diameter between 21 and 27 nm (6). Later studies using cryo-electron
microscopy suggested LDL to have a discoidal or quasi-spherical shape (7,8). The
surface of LDL particle consists of polar, hydrophilic molecules: a single apoB100
molecule, phospholipids (mainly phosphatidylcholine and sphingomyelin), and
unesterified cholesterol. The hydrophobic core consists mainly of cholesteryl esters with
smaller amounts of triglycerides and unesterified cholesterol (9,10).
By definition, small LDL particles contain fewer lipid molecules than large LDL
particles. More specifically, the proportion of cholesteryl ester, free cholesterol, and
phospholipid molecules per LDL particle decreases while the proportion of triglyceride
molecules increases with the decreasing LDL particle size. The relative mass proportion
of protein increases as LDL becomes smaller, since the apoB100 molecule remains in
LDL while the lipids are removed. Moreover, as LDL decreases in size the surface area
covered by apoB100 increases and changes in apoB100 tertiary structure are likely to
occur (9,11).
2.2.2 Determination of LDL subfractions
Electron microscopy (EM) is a direct method to measure LDL size (12). Naturally, EM
is far too elaborate and expensive method to be used for determining LDL size in large
studies or clinical settings. Nondenaturing polyacrylamide gradient gel electrophoresis
(GGE) is a widely used technique that separates LDL particles by size (13). Isolated
LDL or whole plasma can be used in the electrophoresis, after which protein or lipid
stains are used to visualise the LDL particles. In early studies LDL was usually
classified as “large” (pattern A) characterised by a major peak of particle diameter
>25.5 nm with minor smaller peaks, or “small” (pattern B) characterised by a major
peak of particle diameter <25.5 nm with minor larger peaks (14) (Figure 2). If neither
criterion was fulfilled LDL was classified as “intermediate” (pattern I). Later studies
have often favoured using the diameter of the most dominant LDL peak as a continuous
variable. Because additional minor LDL peaks can often be seen using GGE, some
12
25.5 nm
Pattern A (large) Intermediate pattern Pattern B (small)
Figure 2. LDL subclasses in GGE. Modified from Austin et al. (1988)
25.5 nm 25.5 nm
authors integrate the area under each peak (15,16). This gives some additional
information compared with the use of only major peak diameter. However, in most
individuals only one or two peaks can be clearly identified in GGE, and thus the less
elaborate use of the single peak size is justified.
GGE is an inexpensive method to separate LDL subfractions but it takes several
workdays to obtain the results. Due to this limitation alternative methods have been
developed to measure LDL size. The proton nuclear magnetic resonance (NMR)
spectroscopy measures the NMR signals emitted by lipoproteins of different size
(17,18). The measured signals are transformed into particle concentration units
(nanomols per liter) using reference data on isolated lipoproteins. Concentrations of
cholesterol and triglyceride in the particles can also be calculated, although the
calculated lipid concentrations are not accurate if the particle composition is abnormal
(18). The average diameters of lipoprotein particles can also be calculated. Although the
calculated diameter is systematically smaller than that determined by GGE, there is a
good correlation between the methods (r= 0.9) (17). Results of NMR spectroscopy can
be rapidly obtained from a single plasma sample. In addition, there is evidence
suggesting that high LDL particle number and small LDL particle size determined by
NMR are risk factors for cardiovascular disease (19).
A number of density gradient ultracentrifugation (DGUC) procedures have been
developed to divide LDL into subfractions based on density (20). The number of
subfractions and their density intervals vary between the procedures. Compared with
GGE all DGUC procedures are more expensive and elaborate. The advantage of DGUC
is the resolution between subfractions and the possibility to analyse the chemical
composition of each subfraction. LDL size determined by GGE and flotation rate
determined by DGUC correlate relatively well (r= 0.68 to 0.85) (21,22) so that small
particles are dense and large particles are buoyant.
2.2.3 Genetic factors and LDL subfractions
A number of studies have suggested that LDL subfraction distribution is influenced by
hereditary factors (14,23-27). Approximately one third to one half of the variation in
LDL size and density has been estimated to be determined by genetic influence and the
rest by environmental factors (24,26). Whether the genetic factors regulate LDL
subfractions independently of other lipids and lipoproteins or, for example, by
regulating serum triglyceride concentration and causing secondary changes in LDL
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subfraction distribution is not established. The latter theory is supported by the results
of Edwards et al. who found that in families with hereditary hypertriglyceridemia same
genes are likely to contribute to variations in LDL size, and serum concentrations of
triglycerides and HDL cholesterol (28).
Although several candidate genes have been linked with preponderance of small, dense
LDL particles replication of the positive results has often been unsuccessful. Some of
the first reports linked the LDL receptor gene locus to preponderance of small dense
LDL particles (29,30), but further studies have not confirmed these results (31-33).
Mutations in the apoB gene could prolong the residence time of LDL particles in
circulation and subsequently increase the possibility of their modification. One study
has found linkage between apoB gene and LDL size (32), while two studies have
reported a negative result (30,34). Because cholesteryl ester transfer protein and hepatic
lipase are involved in LDL metabolism (see chapter 2.2.4) they have also been studied
extensively. Genetic markers in the promoter and encoding region of HL (35,36) and
CETP (30,37) have indeed been linked to LDL particle size and density, but in other
populations the results have again been negative (32,33,38). Finally, in two studies
heterozygous carriers of defective and null mutations of LPL gene have had smaller
LDL particles than normal subjects (39,40). However, in a study of hyperlipidemic
families no genetic linkage was found between LPL gene and LDL size (33). The lack
of consistent results suggests that several genes affect LDL size interacting with each
other and environmental factors.
2.2.4 Influence of lipoproteins, lipolytic enzymes and lipid transfer proteins on
LDL subfractions
In a number of cross-sectional and follow-up studies the serum triglyceride
concentration has been strongly associated with LDL size (15,16,41-43). In subjects
with fasting serum triglycerides below 1.5 to 1.7 mmol/l LDL particles are typically
large and buoyant, but serum triglyceride level above this level increases the probability
of having small, dense LDL (1,44). Low HDL cholesterol concentration is also common
in individuals with small, dense LDL. The associations between triglyceride and HDL
cholesterol concentrations and LDL particle size may result from both genetic and
metabolic factors (28,41,45).
Lipoprotein lipase does not have a direct role in the modification of LDL particles. The
physiological role of LPL is to hydrolyse fatty acids from triglyceride-rich lipoproteins
(TRL, i.e. chylomicrons and VLDL) and thus it is one of the regulators of serum
triglyceride concentration. Impaired LPL action results in reduced catabolism of TRL.
This in turn increases the CETP-mediated lipid exchange between LDL and TRL.
Therefore, LPL may indirectly affect LDL particle size.
Cholesteryl ester transfer protein mediates the transfer of cholesteryl esters and
triglycerides between triglyceride-rich lipoproteins, LDL, and HDL (46). It is important
in the formation of small, dense LDL because plasma does not contain enzymes that are
able to hydrolyse cholesteryl esters, the most abundant lipid species in LDL. CETP
facilitates the transfer of cholesteryl esters from LDL and HDL to TRL and triglycerides
from TRL to LDL and HDL. As the result of this lipid exchange LDL and HDL
particles become depleted of CE and enriched in triglycerides. Mann et al. have shown
that the plasma triglyceride concentration is the main rate-limiting factor in the lipid
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exchange between LDL and TRL, and that plasma CETP activity becomes rate limiting
only in the presence of hypertriglyceridemia (47).
Hepatic lipase hydrolyses triglycerides and phospholipids from small lipoproteins (IDL,
LDL, and HDL). The enrichment of LDL with triglycerides by CETP makes LDL
particles better substrate to HL, which renders LDL particles smaller and denser. HL
gene promoter polymorphism C514T is associated with decreased HL activity and large
LDL size in some (35) but not all (38) studies. HL activity is also affected by sex
hormones: androgens increase and estrogens decrease HL activity (48). Subjects with
inherited HL deficiency have large, buoyant LDL particles, which provides further
evidence for the role of HL in LDL subfraction regulation (49).
The effects of hypertriglyceridemia, CETP, and HL on the formation of small, dense
LDL particles and low serum HDL cholesterol concentration are summarised in Figure
3.
 Figure 3. Formation of small, dense LDL and small, dense HDL particles.
Hypertriglyceridemia promotes CETP-mediated cholesteryl ester (CE) transfer from
LDL and HDL to triglyceride-rich lipoproteins (TRL) and triglyceride (Tg) transfer
from TRL to LDL and HDL. Subsequently, hepatic lipase hydrolyses Tg and
phospholipids (PL) from LDL and HDL and causes the formation of small, dense
LDL and HDL and low HDL cholesterol.
Tg-rich, CE-poor
LDL
Small, dense LDL
HL
Tg and PL
Elevated
serum
TRL
CETP
Tg
CE
CETPTg
CE
Tg-rich, CE-poor
HDL
Low HDL cholesterol
Small, dense HDL
HL
Tg and PL
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2.2.5 Influence of gender and lifestyle on LDL subfractions
Men have on average smaller and denser LDL particles than women (15,50). There are
at least two possible reasons for this gender difference. First, hepatic lipase activity is
higher in men than in women due to effects of sex hormones (48). Second, men on
average have higher serum triglyceride concentration than women (51,52).
Diet has some influence on LDL size and density. In a cohort of 105 healthy men a six-
week high-fat, low-carbohydrate diet was associated with an increase in the buoyant
LDL subfraction mass compared with a six-week isocaloric low-fat, carbohydrate-rich
diet (53). Plasma triglyceride concentration was higher during the low-fat diet. The
increase in triglyceride concentration was especially high in the subjects in whom LDL
subclass pattern changed from large to small during the carbohydrate-rich diet. The
quality of dietary fatty acids also modulates LDL size but data on the effects of
unsaturated fatty acids on LDL size are controversial. Kratz et al. reported that in
healthy men and women diets rich in olive oil (rich in monounsaturated fatty acids),
rapeseed oil (rich in n-3 polyunsaturated fatty acids (PUFA)), or sunflower oil (rich in
n-6 PUFA) each slightly decrease LDL size compared with a diet rich in saturated fatty
acids (54). Data on changes in serum triglycerides were not reported. Fish oil
supplementation has been reported either to increase LDL size (55) or have no effect
(56). Overall, the diet-induced changes in LDL size and density are modest and mostly
mediated by the concomitant changes in serum triglyceride concentration.
Strenuous exercise such as marathon run or full-length triathlon has in some studies
increased LDL particle size (57,58) while others have reported no significant change in
LDL diameter or dense LDL concentration (59,60). The discrepancy is likely due to
differences in the baseline triglyceride concentration and duration and intensity of
exercise. When changes in LDL size or density have been found, they have correlated
with simultaneous decreases in serum triglyceride concentrations (57,58).
2.2.6 Effects of insulin resistance and type 2 diabetes on LDL subfractions
Insulin sensitivity describes the biological effectiveness of insulin. Insulin has several
metabolic effects, such as inhibition of hepatic glucose and VLDL1 production,
inhibition of lipolysis in adipocytes, and stimulation of glucose uptake in myocytes and
adipocytes. In insulin resistant conditions, such as obesity and type 2 diabetes, the
actions of insulin are attenuated. Subjects with insulin resistance have usually smaller
LDL particles than insulin sensitive subjects of similar age, gender, and body mass
index (BMI) (5,61,62). Importantly, the preponderance of small, dense LDL results
from hypertriglyceridemia and not insulin resistance per se. Patients with type 2
diabetes and nondiabetic subjects with equal triglyceride levels have similar LDL
particle size (63). Type 2 diabetic patients with hypertriglyceridemia have smaller and
denser LDL particles than patients with lower triglyceride concentration and similar
glycemic control (64). In addition, decreasing serum triglyceride concentration without
changing glycemic control causes a shift towards larger, more buoyant LDL particles
(43,65-67). Also, improvement of glycemic control does not affect LDL subfraction
distribution unless it is accompanied by changes in serum triglycerides or HL activity
(68,69).
2.2.7 Effect of familial combined hyperlipidemia on LDL subfractions
Familial combined hyperlipidemia (FCHL) is a hereditary dyslipidemia with an
estimated population prevalence of 0.5 to 2%. Approximately half of the family
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members are affected, and of the affected subjects one third has isolated
hypercholesterolemia (type IIA hyperlipidemia), one third has combined hyperlipidemia
(type IIB), and one third has isolated hypertriglyceridemia (type IV). The diagnosis of
FCHL was originally based on serum total cholesterol and triglyceride concentrations
(70-72). In recent years new definitions based on serum triglyceride and apoB
concentrations and presence of small, dense LDL have been suggested (73-75), but
these guidelines are difficult to use in clinics. FCHL is an oligogenic disease with at
least one major and several modifying gene defects (76,77). Specific genes causing
FCHL are still unknown, but the locus 1q21-23 in chromosome 1 is a strong candidate
for the major gene defect (78-80). Several phenotype-modifying loci have also been
suggested (80-82). In addition, obesity, environmental factors, and gene-environment
interactions are likely to further modify the dyslipidemic phenotype (75,83).
Individuals with FCHL have smaller and denser LDL particles than normolipidemic
control subjects (84). In FCHL families LDL size and density are influenced by both
genetic and environmental factors and small, dense LDL particles are common
especially in subjects with hypertriglyceridemia (85,86). In a study by Bredie et al. 22
FCHL patients were treated with gemfibrozil for 12 weeks, which significantly reduced
their serum triglyceride concentration (from 2.9 ± 0.9 to 1.4 ± 0.4 mmol/l) and caused a
shift towards a more buoyant LDL subfraction profile. Nevertheless, in the majority of
patients LDL profile remained dense. LDL diameter was not measured in that study
(87). Hokanson et al. treated 13 FCHL patients with gemfibrozil for 12 weeks (88),
which decreased serum triglyceride concentration from 4.2 ± 2.2 to 1.9 ± 0.9 mmol/l.
This was accompanied by and inversely correlated with (r= -0.60, p<0.05) an increase
in LDL buoyancy. LDL peak particle diameter also increased slightly, but the change
was not statistically significant. Because the on-treatment triglyceride concentrations
remained relatively high, it is not surprising that LDL size remained small. Together
these small studies suggest that serum triglyceride concentration regulates LDL
properties also in FCHL, probably accompanied by other factors. Since HL and CETP
are involved in the modification of LDL in the general population, they are attractive
candidates to be studied also in subjects with FCHL.
2.2.8 Influence of drugs on LDL subfractions
Fibric acid derivatives (fibrates) decrease serum triglycerides and total cholesterol and
increase HDL cholesterol concentrations (89). They activate peroxisome proliferator-
activated receptor alpha (PPAR-α), which forms a heterodimer with retinoid X receptor.
This complex binds to specific response elements in DNA and regulates gene
expression (90) (Figure 4). Fibrates lower serum triglycerides by 1) increasing FFA
oxidation in the liver thereby probably decreasing the secretion of triglyceride-rich
lipoproteins, and 2) enhancing lipolysis by LPL. The latter action may be mediated by
changes in transcription of LPL, apoC-II and/or apoC-III genes (91). In several studies
the use of fibrates has been associated with a marked reduction in serum triglycerides
(approximately -40%) accompanied with a decrease in small, dense LDL concentration
and an increase in LDL peak particle diameter (43,65,66,92,93).
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (3-HMG inhibitors,
statins) inhibit cholesterol synthesis in the liver (94). Consequently, hepatic LDL
receptors are upregulated and the uptake of LDL, IDL, and VLDL particles from the
circulation is enhanced (95). Statins decrease serum total and LDL cholesterol and to
some extent also serum triglyceride concentrations in a dose-dependent manner (96).
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PPRE Target gene
RXR
PPAR RXRA
B
PPAR
Figure 4. A simplified scheme of PPAR activation and regulation of gene
transcription.
A Ligands bind to peroxisome proliferator-activated receptor (PPAR) and retinoid X
receptor (RXR).
B The PPAR-RXR heterodimere binds to PPAR response elements (PPRE) in the
promoter region of the target gene and regulates gene transcription. Coactivators and
repressors of PPAR, which also regulate PPAR activity, are omitted from the figure.
The effect of statin therapy on LDL subfraction profile depends on the effect on serum
triglycerides and baseline LDL subfraction profile: the increase in LDL size and
decrease in LDL density are most prominent in subjects with greatest decrease in
triglycerides and predominance of small, dense LDL at baseline (93,97-99).
2.3 VASCULAR INJURY AND ATHEROSCLEROSIS
2.3.1 Vascular endothelium and nitric oxide
Vascular endothelium is a monolayer of cells that lines blood vessels. It is a highly
active organ that generates substances such as nitric oxide, prostacyclin, endothelium-
derived hyperpolarising factor (EDHF), thromboxane, and von Willebrand factor that
regulate vasomotion, leukocyte adhesion, platelet function, fibrinolysis, and
inflammation in vascular wall (100). NO-mediated vasodilation is possibly the most
intensively studied feature of endothelial function. NO is generated by endothelial cell
nitric oxide synthase (eNOS) from L-arginine (Figure 5). A variety of stimuli (e.g.
acetylcholine, bradykinin, substance P, serotonin, and laminar shear stress) can activate
eNOS by increasing intracellular concentration of Ca++ in endothelial cells. NO diffuses
to vascular smooth muscle cells and activates guanylate cyclase, which increases the
concentration of intracellular cGMP leading to vasorelaxation (101). Other effects of
NO include inhibition of leukocyte adhesion (102) and platelet aggregation (103). Other
vasoactive substances secreted by endothelium include vasodilatory prostacyclin and
chemically yet unidentified endothelium-derived hyperpolarising factor (EDHF), and
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Figure 5. A simplified scheme of nitric oxide synthase activation and NO action. ACh
and laminar shear stress increase intracellular Ca++ concentration in endothelial cells
and activate NOS. Generated NO diffundates into vessel wall smooth muscle cells
and activates guanylate cyclase. cGMP in turn causes SMC relaxation and
vasodilation.
vasoconstrictory endothelin-1, thromboxane A2, and angiotensin-II (100,104). The
contribution of various vasodilatory substances to vasodilation appears to depend on
vessel size and location. In humans, the vasodilatory action of NO is important
especially in larger conductance vessels, while the contribution of EDHF to vasodilation
increases as the vessel size decreases (105).
2.3.2 Measurement of endothelial function in vivo
Infusion of ACh to healthy human coronary arteries causes vasodilation, which is
largely mediated by NO (106,107). In contrast, in patients with risk factors of
atherosclerosis or coronary artery disease, the endothelium-dependent vasodilation
response to ACh is abolished and vasoconstriction is induced (106,108). Obviously,
study of endothelial function by infusing vasoactive substances to coronary arteries is
limited to patients with symptoms of CAD. However, the forearm vascular bed is more
readily accessible and can be used to study also asymptomatic and healthy subjects.
An invasive and a non-invasive test are commonly used to measure forearm
endothelium-dependent vasodilation in humans in vivo. In the former test drugs that
activate eNOS (such as ACh) are infused into the brachial artery and forearm blood
flow is measured usually by venous occlusion plethysmography (109,110). By
coinfusing L-NMMA, which specifically inhibits NO synthesis (111), 30 to 40 % of the
ACh-induced increase in forearm blood flow is abolished (112). This indicates that both
increased NO production and other mechanisms mediate the vasodilatory action of
ACh. Endothelium-independent vasodilation is assessed by measuring the forearm
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blood flow during the infusion of sodium nitroprusside (SNP) or other drug, which
directly relaxes vascular smooth muscle cells.
In the non-invasive test high-resolution ultrasound is used to measure brachial artery
diameter during postischemic reactive hyperemia (113). Blood flow is measured
proximally to the site of blood flow occlusion. Ischemia increases blood flow, and this
in turn increases the shear stress of endothelium, which activates eNOS. Endothelium-
independent vasodilation is assessed after sublingual administration of glyceryl
trinitrate, the dose of which should be such that it induces a similar increase in brachial
artery diameter as shear stress in healthy subjects. The position of the occlusion cuff
(upper arm or forearm) and the time of the measurement have a significant effect on
dilatation of the brachial artery (114). These considerations make comparison of studies
using the non-invasive method difficult.
In addition to the two aforementioned methods, a novel method to measure endothelial
function noninvasively has been recently described (115,116). It is based on measuring
the radial artery pulse-wave by applanation tonometry (117). Endothelial function is
assessed by inhalation of ß2-agonist, such as albuterol or salbutamol, which increases
the generation of NO (118) and decreases the augmentation index calculated from the
pulse-wave (115,116). The method has good reproducibility and the response to ß2-
agonist inhalation correlates with the forearm blood flow response to acetylcholine
infusion (r= 0.50, p=0.02, n=27) (115,116). Moreover, subjects with
hypercholesterolemia (115) and coronary artery disease (116) have impaired response to
ß2-agonist compared with healthy subjects.
Measurement of serum concentrations of molecules derived exclusively or in part from
endothelium, such as von Willebrand factor, vascular cell adhesion molecule-1
(VCAM-1) and soluble E-selectin, can also be used as a marker of endothelial
activation. However, a recent meta-analysis suggested that measurement of serum
concentrations of soluble cell adhesion molecules does not help in predicting the risk of
future coronary event (119).
2.3.3 Development of atherosclerosis
Increased serum concentration of apoB100 containing lipoproteins, especially LDL, is
an important cause of atherosclerosis. In addition, factors such as hypertension,
hyperglycemia, and smoking also contribute to development of atherosclerosis (120).
Dysfunction of arterial endothelial cells is believed to be an important factor in the
initiation of the disease (121). Therefore, it is crucial to identify the cause(s) of early
endothelial dysfunction. Atherosclerosis is localised especially at bifurcations and other
sites of disturbed or slow blood flow (122,123). It appears that laminar and disturbed
blood flow induce different gene expression profiles in endothelial cells, the former
antiatherogenic and the latter proatherogenic (124,125). An animal model has also
shown that lipid deposition is increased in areas of disturbed blood flow and low shear
stress, and decreased in areas of elevated shear stress (126). LDL particles that enter the
arterial wall are retained by binding to matrix proteoglycans either directly by apoB100
or indirectly with the help of bridging molecules (127,128). Retained LDL particles are
subjected to modification, such as oxidation, proteolysis, lipolysis, and aggregation
(129-131). Modified LDL in turn further activates endothelial cells and increases
recruitment and activation of leukocytes, which leads to a vicious circle of local
inflammation and accumulation of LDL (132,133). Extensively modified lipoproteins
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are ingested by intimal macrophages via scavenger receptor pathway, which is not
downregulated by intracellular accumulation of cholesterol like the LDL receptor
pathway. Excessive ingestion of LDL by macrophages leads to formation of lipid-filled
macrophages, foam cells (Figure 6). Progressive entry, aggregation and fusion of LDL
Lumen
Intima
Binding to PG
and modification
LDL Monocyte
Uptake
of ox-LDL
 Figure 6. A schematic illustration of foam cell formation in atherogenesis. LDL and
monocytes penetrate from blood into arterial intima. LDL is bound to intimal
proteoglycans (PG) and modified by oxidation and other processes. Macrophages
uptake modified LDL (ox-LDL) by scavenger receptors and become lipid-filled foam
cells. Local inflammation increases the entry of LDL and monocytes.
ox-LDL
Foam cell
Macrophage
together with apoptosis of foam cells lead to formation of atheroma, an extracellular
lipid mass. Cytokines and growth factors secreted by lymphocytes, macrophages, and
endothelial cells induce migration and proliferation of smooth muscle cells (SMC) in
affected intima. In later stages atherosclerotic lesions are characterised by presence of
variable amounts of collagen and other connective tissue, the fibrous cap, secreted
mainly by SMC around the atheroma. Although lesions with thick fibrous cap may
significantly occlude vessel lumen and cause ischemic symptoms at exercise, they are
actually not as prone to cause acute myocardial events than less occlusive lesions with
thin fibrous cap and high amount of inflammatory cells (134). The explanation is that
the latter lesions more easily rupture and cause acute thrombus formation in the artery.
Indeed, measurement of C-reactive protein, a marker of inflammation, adds to the
predictive value of serum lipids in predicting myocardial infarction (135,136).
2.3.4 Measurement of coronary atherosclerosis
Coronary angiography is the most commonly used method to visualise atherosclerosis
in coronary arteries although it has several limitations (137). First, the method is
elaborate and invasive and exposes patients to radiation. Second, only 2-dimensional
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silhouette figures of coronary arteries are obtained. Third, initial atheroma often grows
away from vessel lumen and consequently lumen diameter changes only little (138).
Thus, early atherosclerosis is difficult to detect using angiography. Computer-assisted
analysis of angiogram allows reproducible measurements of vessel dimensions and is
therefore superisor to visual analysis, but it cannot overcome the aforementioned
limitations.
Newer methods have the potential to improve diagnosis of coronary atherosclerosis.
Intravascular ultrasound (IVUS) enables visualisation of both vessel lumen diameter as
well as the size and distribution of atheromas in the vascular wall. Lumen diameters
measured by IVUS and angiography are very closely correlated in healthy vessels, and
moderately correlated in diseased ones (r= 0.7 to 0.8) (139). Limitations of IVUS
include its invasive nature and the inability to visualise small vessels and severe
stenoses due to the physical size of the ultrasound catheter. Therefore, IVUS should be
considered as an additional instrument to angiography rather than alternative (139).
Magnetic resonance angiography allows noninvasive three-dimensional visualisation of
the lumen and the wall of coronary arteries without ionising radiation (140). At the
moment its major limitation is the modest ability to image distal segments of coronary
arteries and small lesions (141). Further studies and development of the technique
determine its clinical value in the future (142).
2.3.5 Small, dense LDL particles as a risk factor for atherosclerosis
High serum total and LDL cholesterol concentrations increase the risk of atherosclerosis
(143-146). In addition to the quantity of these apoB-containing lipoproteins, the quality
of LDL particles has been associated with atherosclerosis and cardiovascular disease. In
several cross-sectional studies subjects with coronary artery disease (CAD) have had
smaller and denser LDL particles than controls (44,147-150). However, other
dyslipidemias, especially high serum triglyceride and low HDL cholesterol
concentrations are common in subjects with small LDL, which explains part of their
increased CAD risk (147-150). In addition, in one study LDL size was similar in
American Indians with and without CAD (151), and in another study subjects with
CAD had larger LDL particles than those without CAD (152). Differences in study
populations, such as ethnicity, serum cholesterol and triglyceride concentrations, and
age probably explain some of the discrepancy between the results.
More information on the impact of small, dense LDL particles on atherosclerosis has
been obtained from prospective studies in which initially healthy subjects who had a
cardiovascular event during the follow-up (cases) have been compared with subjects
who did not have the event (controls). In the Physicians’ Health Study 266 cases (mean
LDL size 25.6 ± 0.9 nm) were compared with 308 control men matched for age and
smoking (mean LDL size 25.9 ± 0.8 nm) (153). Small LDL particle diameter was a
significant predictor of MI during the 7-year follow-up after adjustment for age,
smoking, HDL and total cholesterol, but not after adjustment for triglycerides. The
Stanford Five-City Project included 90 male and 34 female cases (154). They had on
average 0.51 nm smaller LDL particles (26.17 ± 1.00 vs. 26.68 ± 0.90 nm, p<0.001)
than controls matched for age, sex, and ethnicity. The case-control difference in LDL
size remained significant after controlling for plasma triglycerides, HDL and non-HDL
cholesterol, smoking, systolic blood pressure, and body mass index, but not after
adjusting for the total cholesterol to HDL cholesterol ratio. In the Honolulu Heart
Program 145 Japanese-American male cases were compared with 296 controls (155).
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Smaller LDL particles at baseline were a predictor of coronary heart disease in
univariate analysis (relative risk for 1 nm decrease in LDL size 1.28, 95% confidence
interval 1.01 to 1.63), but not after adjustment for other CAD risk factors. The Québec
Cardiovascular Study has produced three prospective reports supporting an independent
role of small LDL particles as a predictor of ischemic heart disease (IHD) events (156-
158). In the first paper the presence of small LDL particles (smallest LDL tertile with
diameter ≤25.64 nm vs. largest LDL tertile with diameter >26.05 nm) significantly
predicted IHD during a 5-year follow-up period after adjustment for non-lipid risk
factors (p<0.01), but not after adjustment for plasma triglycerides, HDL cholesterol, and
apoB (p=0.08) (156). In the cohort study of 2057 men (2nd paper) those with small LDL
particles (<25.6 nm) had a significantly higher risk of future IHD than those with large
LDL particles (157). The risk was statistically significant after adjustment for non-lipid
risk factors and LDL cholesterol, HDL cholesterol, triglycerides, apoB, or total
cholesterol to HDL cholesterol ratio. The presence of small LDL particles increased the
risk of IHD associated with traditional lipid risk factors. In the third paper St-Pierre et
al. compared various electrophoretic properties of LDL particles as a predictor of IHD
using 108 cases and 1926 controls (158). They calculated the concentration of
cholesterol among small LDL particles (diameter < 25.5 nm) by multiplying the total
plasma LDL cholesterol levels by the relative proportion of LDL with a diameter < 25.5
nm. This variable, which reflected both the quantity and the quality of LDL, was
strongly associated with the risk of IHD after adjustment of non-lipid (relative risk 6.2,
p<0.001, 1st tertile vs. 3rd tertile) and non-lipid and lipid risk factors (relative risk 4.6,
p<0.001). In contrast, in the study by Mykkänen et al. in which elderly subjects were
followed for 3.5 years, LDL particle size was similar in cases who had a coronary heart
disease event (n=86) and controls matched for age and presence or absence of diabetes
(n=172) (159). Moreover, in the Cholesterol and Recurrent Events (CARE) trial large
LDL particles predicted coronary events in the 460 subjects receiving placebo for the 5-
year follow-up, but not in the subjects receiving pravastatin or when both placebo and
pravastatin groups were analysed together (160). The participants in the CARE trial had
already had a verified myocardial infarction, whereas in the other studies subjects were
free of known atherosclerotic disease at baseline. Table 1 summarises results of these
prospective studies.
Three relatively small studies have evaluated whether lipid-lowering treatment, which
decreases the concentration of dense LDL and increases LDL particle size, is associated
with the progression of coronary artery disease (92,161,162). In the Monitored
Atherosclerosis Regression Study (MARS), which included 220 subjects, the on-
treatment mass of the dense LDL fraction was associated with angiographic progression
of CAD in univariate correlation analysis but not in multivariate analysis (161). In the
Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), which included 81
men, no association was found between on-trial LDL peak particle size and progression
of CAD during a 5-year follow-up period (92). In both of these studies plasma lipids
and lipoproteins explained only a small part of CAD regression. In contrast, Zambon et
al. found that an increase in LDL buoyancy, reflecting a shift towards larger LDL
particles, was strongly inversely associated with the progression of CAD in the Familial
Atherosclerosis Treatment Study (FATS) (162). The change in LDL buoyancy
explained 37% of the variance in CAD severity in multivariate analysis. The results of
Zambon et al. should be interpreted cautiously, however, because the study comprised
only 83 subjects.
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2.3.6 Atherogenic characteristics of small LDL particles
Small, dense LDL particles have several characteristics that may increase their
atherogenic potential. The conformation of apoB100 is different in small and large LDL
particles (9,163,164). The change in apoB100 structure decreases the binding affinity of
small LDL particles to the LDL receptor (163,165) and increases the residence time of
LDL particles in plasma. Consequently, small LDL particles have more time to infiltrate
from circulation to the arterial wall. The smaller particle size itself may also facilitate
the infiltration of small, dense LDL particles to the intima (166). Binding of lipoproteins
to matrix proteoglycans is important in the formation of atherosclerotic lesions (167).
The binding is initially direct and probably mediated by clusters of positively charged
arginine and lysine residues in apoB (168). Importantly, small, dense LDL particles
have a higher binding affinity to intimal proteoglycans than large LDL particles
(165,169,170). This phenomenon is probably mediated by changes in apoB100 tertiary
structure that reveal novel proteoglycan binding sites (9,164). In addition to direct
binding to intimal proteoglycans, indirect binding via bridging molecules such as
lipoprotein lipase and decorin markedly increases the retention of LDL in the arterial
wall (128,168). As discussed above, the retained lipoproteins in the intima are exposed
to modification, such as oxidation and hydrolysis of lipids and apoB100, which cause
their fusion to lipid droplets and increase their uptake by macrophage scavenger
receptors and foam cell formation (10,167,168). The susceptibility of small, dense LDL
particles to oxidation is an additional mechanism by which they may be more
atherogenic than large, buoyant LDL (171).
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3. AIMS OF THE STUDY
The present study was undertaken to investigate metabolic factors that regulate LDL
particle size and the possible associations of LDL size and atherosclerosis. In particular,
the following questions were addressed:
1) Are the activities of hepatic lipase, lipoprotein lipase, cholesteryl ester transfer
protein, and phospholipid transfer protein associated with LDL particle size in
subjects with familial combined hyperlipidemia (Study I)?
2) Does postprandial hypertriglyceridemia cause an acute change in LDL particle size,
and is it possible to attenuate postprandial hyperlipemia by oral insulinotropic drugs
in subjects with type 2 diabetes (Study II)?
3) Is LDL particle size associated with endothelium-dependent vasodilatory
dysfunction and insulin resistance in healthy men (Study III)?
4) Is forearm endothelium-dependent vasodilation impaired in men with type 2
diabetes, and if so, which metabolic characteristics are associated with this
impairment (Study IV)?
5) Is LDL particle size associated with progression of coronary artery disease as
measured by quantitative angiography in subjects with type 2 diabetes (Study V)?
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4. SUBJECTS AND STUDY DESIGNS
Study I
FCHL probands were recruited from patients undergoing elective coronary angiography
or from angiography registers in Helsinki University Central Hospital and Turku
University Central Hospital. The inclusion criteria were: 1) age 30 to 60 years; 2) at
least 50% stenosis in at least one coronary artery in the angiogram or clinically verified
coronary artery disease; 3) serum total cholesterol (TC) and/or triglyceride (Tg) level ≥
90th age- and gender- specific percentile without lipid-lowering medication; 4) at least
three accessible first-degree relatives. Exclusion criteria for the probands were hepatic,
renal, and thyroid disease and type 1 diabetes. Familial hypercholesterolemia was
excluded by the lymphocyte culture method (172). The serum lipid levels of the first-
degree relatives were determined in the second phase of the recruitment. If there were at
least two subjects with TC or Tg ≥ 90th age- and gender- specific percentile the family
was classified as FCHL (unless all affected family members had isolated
hypercholesterolemia). In the third phase all accessible relatives were examined.
The subjects included in study I represent a subgroup of all FCHL family members.
They did not have type 1 or type 2 diabetes or use lipid-lowering medication, hormone
replacement therapy, or oral contraceptives. In all, there were 68 affected (TC or Tg ≥
90th age- and gender- specific percentile) and 78 nonaffected (TC and Tg ≤ 90th age- and
gender- specific percentile) family members and 45 spouses from 37 FCHL families.
Their fasting serum lipid concentrations, postheparin serum LPL and HL activities,
plasma CETP activity and plasma PLTP activity and mass were measured from samples
obtained in the same day. Subject characteristics are shown in Table 2.
Table 2. Subject characteristics (Study I).
FCHL affected FCHL nonaffected Spouse P value*
Age, years 42.3 ± 12.4 ab 32.4 ± 12.3 50.2 ± 7.6 <0.001
BMI, kg/m2 27.0 ± 3.9 24.7 ± 4.0 25.9 ± 4.4 0.03
TC, mmol/l 6.47 ± 0.98 4.92 ± 0.92 5.54 ± 1.02 -
LDL-C, mmol/l 3.98 ± 0.90 ab 3.12 ± 0.74 3.61 ± 0.87 <0.001
HDL-C, mmol/l 1.26 ± 0.30 a 1.35 ± 0.29 1.38 ± 0.29 0.03
Tg, mmol/l 2.50 ± 1.50 1.10 ± 0.47 1.25 ± 0.47 -
apoB, g/l 12.7 ± 2.7 ab 8.5 ± 2.3 9.7 ± 2.4 <0.001
LDL size, nm 25.3 ± 1.5 ab 26.8 ± 1.2 26.6 ± 1.2 <0.001
*ANCOVA with age as covariate, Bonferroni post hoc adjustment for multiple comparisons.
ap<0.05 FCHL affected vs. FCHL nonaffected; bp<0.05 FCHL affected vs. spouse.
Study II
The study population consisted of 48 men and women with type 2 diabetes treated
previously with diet or oral monotherapy. Subjects that had hypoglycemic medication
had a wash-out period of at least 6 weeks. Inclusion criteria were: 1) HbA1c 6.5 to 10 %
without hypoglycemic medication; 2) fasting serum glucose <15 mmol/l; apolipoprotein
E phenotype 3/3 or 3/4. Exclusion criteria were: 1) serum total cholesterol > 6.5 mmol/l;
2) serum total triglycerides > 4.5 mmol/l; 3) BMI > 33 kg/m2; 4) smoking or use of
nicotine therapy; 5) use of lipid-lowering medication, hormone replacement therapy,
nonselective beta-blockers, or insulin.
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After a 6-week wash-out period the subjects were randomly assigned to either
nateglinide 120 mg three times daily or glibenclamide 5 mg once or twice daily at
meals. At the randomisation visit subjects had the first oral fat tolerance test (see
chapter 5.4). Study medication was started the following morning. In the glibenclamide
group (randomised n=24) subjects received glibenclamide 5 mg at breakfast for the first
4 weeks. If fasting serum glucose at week 4 was ≥7.0 mmol/l the glibenclamide dose
was increased to 5 mg at breakfast and at dinner. They also received placebo tablets
mimicking nateglinide for the whole 12-week study. In the nateglinide group
(randomised n=24) subjects received nateglinide 120 mg tablets before breakfast, lunch,
and dinner and placebo capsules mimicking glibenclamide for the whole 12-week study.
Postheparin lipolytic enzyme activities were measured from blood samples obtained at
separate visits approximately 7 days before the fat tolerance tests. From the nateglinide
group 1 subject discontinued the study due to unsatisfactory therapeutic effect. From the
glibenclamide group 1 subject discontinued due to unsatisfactory therapeutic effect, 2
subjects due to repeated hypoglycemia, and 1 subject due to convulsions that were
possibly related to hypoglycemia. Only the subjects with both baseline and week 12
data available (n=23 in the nateglinide group, n=20 in the glibenclamide group) were
included in the analyses. Subject characteristics at baseline are shown in Table 3.
Table 3. Baseline subject characteristics (Study II).
Nateglinide Glibenclamide
Age, years 63±8 63±10
BMI, kg/m2 27.8±3.4 28.8±3.5
Glucose, mmol/l 10.1±2.7 10.0±2.5
HbA1c, % 7.6±1.0 7.6±1.0
Insulin, mU/l 10.7±4.6 10.3±4.0
FFA, mmol/l 806±214 781±265
Total triglycerides, mmol/l 1.75±0.44 1.86±0.71
Total cholesterol, mmol/l 5.16±0.70 4.86±0.57
LDL cholesterol, mmol/l 2.85±0.49 2.58±0.39
HDL cholesterol, mmol/l 1.31±0.29 1.21±0.26
Study III
The study evaluated the associations between LDL particle size, serum lipids and
lipoproteins, insulin-stimulated whole-body glucose uptake, and endothelial function in
34 healthy men. Exclusion criteria were: 1) signs or symptoms of cardiovascular
disease; 2) smoking; 3) use of lipid-lowering or cardiovascular drugs; 4) blood pressure
>160/90 mmHg; 5) diabetes, hepatic, or renal disease. Fasting blood samples for the
analysis of lipids and lipoproteins were obtained immediately before the endothelial
function test. Insulin-stimulated whole-body glucose uptake was measured using the
euglycemic hyperinsulinemic clamp technique (173) on a separate day. Subject
characteristics are shown in Table 4.
Study IV
Study subjects were 30 men with type 2 diabetes treated with diet alone (n=18) or diet
and oral medication (n=12) and 12 healthy men. Hypoglycemic medication was
discontinued for 2 days before the study. Exclusion criteria were: 1) signs or symptoms
of cardiovascular disease; 2) blood pressure >160/90 mmHg; 3) symptoms of
neuropathy; 4) macroalbuminuria (albumin excretion rate >200 µg/min in at least one of
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the three overnight urine collections); 5) use of lipid-lowering or cardiovascular drugs;
6) smoking. Six patients had microalbuminuria (mean albumin excretion rate 20 to 200
µg/min in three overnight urine collections) and two had cardiovascular autonomic
neuropathy. Fasting blood samples for the analysis of lipids, lipoproteins, LDL
oxidation in vitro, and plasma antioxidants were obtained immediately before the
endothelial function test. Subject characteristics are shown in Table 5.
Table 4. Subject characteristics (Study III).
LDL size ≤25.5 nm LDL size >25.5 nm
LDL size (nm) 24.4±1.0 26.7±0.7
Age (years) 50±12 55±8
Body mass index (kg/m2) 27.0±2.2 26.7±3.2
Systolic blood pressure (mmHg) 129±17 131±23
Diastolic blood pressure (mmHg) 80±8 80±9
Plasma glucose (mmol/l) 5.7±0.3 5.7±0.7
M-value† (mg/kg body weight⋅minute) 4.2±1.3 5.9±2.0*
Total cholesterol (mmol/l) 5.80±0.73 5.51±1.11
VLDL cholesterol (mmol/l) 0.64±0.22 0.34±0.23**
LDL cholesterol (mmol/l) 3.87±0.58 3.68±0.96
HDL cholesterol (mmol/l) 1.07±0.35 1.30±0.32
Total triglycerides (mmol/l) 1.92±0.55 1.24±0.56*
VLDL triglycerides (mmol/l) 1.40±0.51 0.77±0.51**
†Insulin-stimulated whole-body glucose infusion rate.
*p<0.05 vs. subjects with LDL size ≤25.5 nm.
**p<0.01 vs. subjects with LDL size ≤25.5 nm.
Table 5. Subject characteristics (Study IV).
Patients with type 2 Control subjects
Duration of diabetes (years) 3.5±3.8 -
Age (years) 51±6 51±5
Body mass index (kg/m2) 27.8±2.4 27.1±2.3
Plasma glucose (mmol/l) 9.4±3.0 5.6±0.4
HbA1c (%) 7.4±1.4 5.4±0.4
Systolic blood pressure (mmHg) 138±16 127±12*
Diastolic blood pressure (mmHg) 86±8 81±7*
Total cholesterol (mmol/l) 5.38±1.06 5.69±0.85
LDL cholesterol (mmol/l) 3.21±0.83 3.89±0.67*
HDL cholesterol (mmol/l) 1.17±0.29 1.23±0.33
Total triglycerides (mmol/l) 2.22±1.91 1.27±0.63*
LDL size (nm) 26.2±1.0 26.8±1.2*
*p<0.05 vs. patients with type 2 diabetes
**p<0.01 vs. patients with type 2 diabetes
Study V
The study was a post hoc analysis of the Diabetes Atherosclerosis Intervention Study
(DAIS) (174). DAIS included 418 men and women with type 2 diabetes aged 40-65
years, with or without previous coronary intervention (coronary-artery bypass grafting
or percutaneous transluminal coronary angioplasty). The lipid entry criteria were: total
cholesterol/HDL cholesterol ratio of four or more, plus either LDL cholesterol 3.5-4.5
mmol/l and triglyceride concentration of 5.2 mmol/l or less, or a triglyceride
concentration of 1.7-5.2 mmol/l and LDL cholesterol 4.5 mmol/l or less. Eligible
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patients were randomly assigned to micronised fenofibrate (200 mg once daily) or
placebo for at least three years. The average time between baseline and final angiograms
was 40 months. Progression of coronary artery atherosclerosis was analysed by
quantitative angiograms (175). Out of the 418 randomised patients, 405 (207 placebo,
198 fenofibrate) patients had LDL size measurements at baseline and either at the end of
the study or after at least 1 year of treatment. Out of the 405 patients, 379 had a final
angiogram. For the 26 (12 placebo, 14 fenofibrate) patients with a missing final
angiogram, imputed values were used obtained from the data of the placebo group. Two
subjects in the fenofibrate group and four subjects in the placebo group were excluded
from analyses that required plasma apoB levels due to missing data. The lipid and
lipoprotein levels and LDL particle size measured at the randomisation visit were used
as the baseline data. All available values during the treatment period were used to
calculate mean on-treatment lipid levels. Subject characteristics at baseline are shown in
Table 6.
Table 6. Baseline subject characteristics (Study V).
Placebo
n = 207
Fenofibrate
n = 198
Total
n = 405
Male / Female 154 / 53 144 / 54 298 / 107
Age, years 56 ± 6 57 ± 6 57 ± 6
BMI, kg/m2 28.7 ± 3.2 28.9 ± 3.2 28.8 ± 3.2
Systolic blood pressure, mmHg (*) 140 ± 18 140 ± 19 140 ± 18
Diastolic blood pressure, mmHg (*) 81 ± 9 82 ± 9 82 ± 9
Fasting glucose, mmol/l 9.0 ± 2.6 8.5 ± 2.2 8.8 ± 2.5
HbA1c, % 7.5 ± 1.3 7.5 ± 1.1 7.5 ± 1.2
(*) n=205 (placebo), 195 (fenofibrate), 400 (total)
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5. METHODS
5.1 Measurement of LDL peak particle diameter
LDL peak particle diameters were determined on linear 1 mm thick 2% to 10% gradient
gels. The vertical slab gels were run in the Bio-Rad Mini-Protean II Electrophoresis Cell in
a cooled room at +4°C. Pre-electrophoresis (20 min at 30 V) and electrophoresis (18 hours
125 V) were performed by using Tris-Glycine buffer pH 8.3 (0.024 mol/l Tris and 0.192
mol/l Glycine). Serum samples were stored in -80°C and diluted with sample buffer
containing 0.6 mol/l Tris pH 8.3, 8% sucrose and 0.035% bromphenol blue. 10 µl of
diluted sample was applied to each well. Wells closest to the edges of the gel were not
used. In Studies I-IV the gels were stained with newly filtered Sudan Black B lipid stain
(0.3% Sudan Black B and 1% Zn-acetate in 30% methanol, 30% 2-propanol) for one hour
and destained with 30% 2-propanol for 24 hours. In study V gels were stained with
Coomassie Brilliant Blue protein stain. After destaining gels were kept in 5% acetic acid
for 4-6 hours and dried with Bio-Rad GelAir Drying System for 4 hours. Two isolated
LDL samples were used as a size reference on each gel. Reference LDL was isolated by
ultracentrifugation and dialysed against 0.9% NaCl containing 0.01% EDTA, 8% of
sucrose was added to the dialysed LDL. The particle sizes of the two standard samples
were measured by EM (12). The median of the LDL particle diameters was calculated by
measuring diameters of at least 100 LDL particles from the EM photograph. Dried gels
were photographed with a Kodak Digital Science DC120 camera and analysed with a
Kodak Digital Science Electrophoresis Documentation and Analysis System 120. The
major peak diameter of the sample LDL (LDL size) was determined by comparing the
mobility of the sample to the mobility of the reference LDL preparations run on each gel.
In addition, a control LDL sample was run on each gel. The intragel and intergel
coefficients of variation were <2%.
5.2 In vivo endothelial function test
In vivo endothelial function was determined by measuring forearm blood flow responses
to intra-arterial infusions of endothelium-dependent and -independent vasodilators. The
study was begun after a 10-12 hour fast at 8.00 a.m. Venous blood samples were
withdrawn for measurement of plasma glucose and serum insulin concentrations, and
for the other laboratory analyses. A 27 gauge unmounted steel cannula (Coopers Needle
Works, Birmingham, U.K.), connected to an epidural catheter (Portex, Hythe, Kent,
U.K.), was inserted into the left brachial artery. Subjects rested supine in a quiet
environment for 30 minutes after needle placement before blood flow measurements.
Saline, sodium nitroprusside and acetylcholine (alone and together with N-monomethyl-
L-arginine) were infused as illustrated in Figure 7 at a constant rate of 1 ml/min with
infusion pump (Braun AG, Mesungen, Germany). Forearm blood flow was recorded for
10 seconds at 15-second intervals during the last 3 minutes of each drug and saline
infusion period with mercury-in-rubber strain-gauge venous occlusion plethysmography
(EC 4 Strain Gauge Plethysmograph, Hokanson, Bellevue, WA) combined with a rapid
cuff inflator (E 20, Hokanson), an analog-to-digital converter (McLab/4e, AD
Instruments Pty Ltd, Castle Hill, Australia) and a personal computer (176). The
measurement was performed simultaneously in the infused (experimental) and
uncannulated control arm. Blood flow in the control arm did not significantly change
during the studies. The mean of the final five measurements of each recording period
was used for analysis. In addition, in Study IV reactive (2 and 5 minutes ischemia)
hyperemic forearm blood flow was determined as a measure of maximal vasodilatory
capacity.
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Figure 7. Design of the endothelial function test. Saline, SNP, ACh and L-NMMA
were infused into brachial artery of the nondominant arm. Blood flow was recorded
simultaneously in both forearms for the last three minutes of each infusion.
5.3 Whole-body insulin sensitivity of glucose uptake
Whole body insulin sensitivity of glucose uptake was measured by the euglycemic
hyperinsulinemic clamp technique (173). The study began at 8.00 a.m. after a 12 hour
fast. Insulin and glucose were infused through an 18-gauge catheter (Venflon, Viggo-
Spectramed, Helsingborg, Sweden) inserted into the left antecubital vein. The left hand
was kept in a heated chamber (65°C), and blood samples were withdrawn from a
catheter inserted retrogradely into a heated dorsal hand vein. Insulin (Actrapid Human,
Novo Nordisk) was infused in a primed continuous fashion for 120 minutes (173). The
rate of the continuous insulin infusion was 1 mU/kg⋅min. During hyperinsulinemia
normoglycemia (5 mmol/l) was maintained by adjusting the rate of an intravenous 20%
glucose infusion based on plasma glucose measurements performed at 5-minute
intervals. The glucose infusion rate needed to maintain normoglycemia during the final
30 minutes (90 to 120 minutes) of hyperinsulinemia was used as the measure of whole
body insulin sensitivity index (M-value) (173).
5.4 Oral fat tolerance test
The test started at 8.00 a.m. after an overnight 12-hour fast. Alcohol intake or vigorous
exercise was not allowed during the previous 72 hours. The test meal consisted of bread,
butter, cheese, sliced sausage, egg, paprika, soured whole milk, orange juice, and coffee.
It contained 63 g fat (polyunsaturated fat / saturated fat ratio 0.08), 490 mg cholesterol,
25 g carbohydrate, and 35 g protein, and it was consumed within 10 minutes. After the
test meal the participants were allowed to drink only water until the last blood samples
were collected. Fat tolerance tests were performed in the Study II at the randomisation
visit and on the final visit at 12-weeks on-trial. At the randomisation visit subjects did
not take any medication before the test meal and at the final visit they took the
randomised study drug 5 minutes before the test meal. Blood samples were drawn from
a catheter placed in an antecubital vein at 0 h, 30 min, 1 h, 3 h, 4 h, 6 h, and 8 h (at 30
min and 1 h only samples for glucose, insulin, and FFA were collected). Plasma was
separated within 20 minutes by low-speed centrifugation. The samples were stored at -
80°C unless they were analysed immediately.
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5.5 Quantitative coronary angiography
Coronary angiograms in Study V were evaluated using a computer-assisted quantitative
system (175,177). The coronary tree was divided into segments according to the
recommendations of the American Heart Association. One observer measured
simultaneously from baseline and end-of-study angiograms 1) reference lumen diameter
(diameter of healthy artery), 2) minimum lumen diameter (most severe narrowing), and
3) mean (integrated) lumen diameter of each segment. The most severe narrowing, as a
percentage of the neighbouring reference lumen diameter, was the percentage diameter
stenosis (177). Average per-patient values of minimum and mean lumen diameters and
percentage diameter stenosis were used in the analyses.
5.6 Serum and plasma lipid and lipoprotein concentrations
Density gradient ultracentrifugation was used to isolate serum (178,179) (Studies I, III
and IV) and plasma (180) (Study II) lipoprotein subfractions. Cobas Mira automatic
analyser and enzymatic methods were used to measure cholesterol (Unimate 7 CHOL,
Hoffman-La Roche, Basel, Switzerland), triglyceride (Unimate 7 TRIG, Hoffman-La
Roche, Basel, Switzerland), free cholesterol (Boehringer Mannheim, Mannheim,
Germany), and phospholipid (Wako Chemicals, Neuss, Germany) concentrations in
lipoprotein fractions. Immunoturbidimetric kits were used to measure total apoB (Orion
Diagnostica, Espoo, Finland) and apoAI and apoAII (Boehringer Mannheim,
Mannheim, Germany) concentrations. In Study V plasma lipid and lipoprotein samples
were analysed in two laboratories, one in Helsinki and one in Vancouver (181). The
phosphotungstic acid/MgCl method was used as the precipitating agent for the
measurement of HDL cholesterol. Total and HDL cholesterol and total triglyceride
concentrations were measured using enzymatic methods by Kone/OLL1C848 (Helsinki)
and Hitachi 911 (Vancouver) automatic analysers. LDL cholesterol concentration was
determined by Friedewald calculation (182). Plasma apoB100 was measured by
immunoturbidometric method and Cobas Mira automatic analyser (Helsinki) and
nephelometric method and Beckman Array automatic analyser (Vancouver).
In study II plasma apoB48 and apoB100 concentrations in lipoprotein subfractions were
measured using the method of Karpe et al. (183) with slight modifications (180).
Plasma lipoprotein subfractions were isolated by density gradient ultracentrifugation.
Delipidated aliquotes of samples were dissolved in buffer and run in 3.5 to 20% sodium
dodecyl sulphate polyacrylamide gel electrophoresis. Gels were stained with Coomassie
blue and destained in an aqueous solution of 7% acetic acid and 12% methanol for 24
hours. Gels were scanned with a computer-assisted laser scanning densitometer (Image
Quant 3.19, Molecular Dynamics, Sunnyvale, CA) at 595 nm. Densities of the peaks
representing apoB48 and apoB100 were integrated automatically from the image after
manual removal of background. The absorbance was expressed as the area under the
curve (AUC). Six standard samples of highly concentrated LDL apoB (range 0.125 to
0.75 µg of apoB100) were included in each run. Concentrations of sample apoB48 and
apoB100 were calculated from AUCs using linear regression equation.
5.7 LDL oxidation in vitro, plasma antioxidant concentrations and total peroxyl
radical-trapping capacity (TRAP)
LDL was isolated by short-run density ultracentrifugation. In vitro LDL oxidation was
performed using a modification of the procedure described by Esterbauer et al. (184).
LDL oxidation was initiated by adding freshly prepared CuSO4 (final concentration of
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10.64 µmol/l) to the LDL subfraction, the protein concentration of which was similar in
all subjects. The formation of conjugated dienes was followed by monitoring the change
in absorbance at 234 nm in a motorised Schimadzu spectrophotometer (UV 1201;
Kyoto, Japan) equipped with a 6-cuvette cell connected to a microcomputer at 24°C.
Absorbance was recorded every 1.5 min. The change in absorbance at 234 nm over time
can be divided into three consecutive phases: lag phase, propagation phase, and
decomposition phase (184). The resistance of LDL to oxidation was judged from the
length of the lag time before propagation of the reaction. Plasma concentrations of α-
tocopherol, β-carotene, and retinol were measured by reverse-phase high-pressure liquid
chromatography (HPLC), as described by Schäfer-Elinder and Walldius (185). A
Hewlett-Packard reverse-phase HPLC column (ODS Hypersil 5 µm, 200 mm·2.1 mm)
connected to a Waters HPLC system consisting of an M600 controller, M486 tuneable
UV-absorbance detector, M717+ autosampler, and a Millenium 2010 single-system
chromatography manager (Waters, Milford, MA) were used. The UV detector was set at
326 nm for retinol, 292 nm for α-tocopherol, and 450 nm for β-carotene. Lipid-
standardised α-tocopherol was calculated by dividing the α-tocopherol concentration by
the sum of serum total cholesterol and triglyceride concentrations. Serum total ascorbic
acid (ascorbate and dehydroascorbate) was measured using the spectrophotometric
method of Denson and Bowers (186). Serum sulfhydryl groups were determined as
described by Ellman (187). Plasma uric acid concentrations were measured by an
enzymatic colorimetric assay (Roche Unimate 5 UA; Roche, Neuilly-sur-Seine, France).
The combined capacity of all antioxidants to neutralise free radicals in serum, observed
total peroxyl radical-trapping capacity (TRAPobs), was determined
spectrophotometrically (185,188). The method uses a free radical probe,
dichlorofluorescein-diacetate, the oxidation of which by radicals from the azo-
compound 2,2’ -diazobis (2-amidinopropane) dihydrochloride generates highly
fluorescent dichlorofluorescein diacetate. The latter compound also has absorbance at
504 nm, enabling spectrophotometric quantitation. To estimate to what extent observed
changes in circulating antioxidants explained changes in TRAPobs, the contribution of
each antioxidant to TRAP was calculated by multiplying its concentration by its
stochiometric value (molar amount of free radicals trapped by mole of each antioxidant)
(calculated TRAP, TRAPcalc) (188).
5.8 Other analytical methods
Postheparin HL and LPL activities were measured by the method described by Huttunen
et al. (189). Subjects were injected an intravenous bolus of heparin (100 IU/kg) after an
overnight fast. HL and LPL activities were measured from blood samples drawn 15
minutes after heparin injection. CETP and PLTP activities were determined from fasting
plasma by using radiometric assays (190,191). Serum glucose was determined in Study
II by hexokinase method (Gluco-quant HK, Roche Diagnostics) Plasma glucose was
measured in Studies III and IV by the glucose oxidase method (Beckman Glucose
Analyzer II, Fullerton, CA). Serum insulin concentrations were measured by
radioimmunoassay (Pharmacia Insulin RIA kit). Serum FFA concentrations were
measured by the microfluorometric method of Miles et al. (192). HbA1c was measured
by high-performance liquid chromatography (BioRad Glycosylated Hemoglobin
Analyzer System).
5.9 Statistical analyses
Significances of differences between two groups were tested using unpaired t-test in
Studies II (baseline comparisons), III and IV, and analysis of covariance (ANCOVA)
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with baseline value, centre, gender, and history of previous coronary intervention as
covariates in Study V. In Study I subject characteristics, lipolytic enzyme and lipid
transfer protein activities between affected and nonaffected FCHL family members and
spouses were compared by ANCOVA with age as a covariate followed by Bonferroni
(equal variances) or Tamhane (nonequal variances) post hoc tests when appropriate.
Between-group postprandial responses in Study II and blood flow responses in Study III
were assessed by repeated-measures ANOVA as described by Ludbrook (193).
Univariate correlation analyses were calculated by Pearson’s correlation coefficient in
Studies I, II, III, and V and by Spearman’s correlation coefficient in Study IV. In Study
I correlations between LDL size and other variables were adjusted for age because age
and LDL size were significantly correlated (r= -0.28, p=0.02). Multivariate linear
regression analyses were performed to identify the independent determinants of LDL
size, forearm blood flow, and progression of CAD.
The subjects in Study I were obtained from a family material and related to each other,
and therefore did not fulfil the assumption of independence. From each pedigree there
were 1 to 6 (2 on average) affected subjects in the study. Because the number of related
subjects was low mathematical models were not used to treat the non-independence. To
confirm the results obtained from family data correlation and regression analyses were
recalculated using only one randomly chosen affected subject from each family.
Data are expressed as mean ± standard deviation in text and tables and as mean ±
standard error of the mean in figures. Areas under the curve (AUC) and incremental
areas under the curve (IAUC) in Study II were calculated using the trapezoid rule (194).
Variables with skewed distribution were log-transformed before the analyses.
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6. RESULTS
6.1 Serum lipids, lipoprotein modifying enzyme activities, and LDL particle size in
patients with familial combined hyperlipidemia
Serum lipoproteins and plasma enzyme activities
Affected FCHL family members had by definition higher serum total cholesterol and
triglyceride concentrations than nonaffected family members and spouses. LDL size
was significantly smaller in affected FCHL family members than in nonaffected FCHL
family members or spouses (Table 2). LDL size was particularly small in patients with
phenotype IIB or IV, i.e. in those with hypertriglyceridemia, although the difference
was not statistically significant (25.3 ± 1.5 nm, 25.0 ± 1.4 nm, and 25.0 ± 1.6 nm for
phenotypes IIA, IIB, and IV, respectively, p=0.07). Postheparin plasma HL and LPL
activities as well as fasting plasma CETP and PLTP activities were similar in affected
and nonaffected FCHL family members and spouses (Table 2 of original publication I).
Associations between serum lipids, lipoprotein modifying enzyme activities, and LDL
particle size in FCHL patients
Serum triglyceride, VLDL cholesterol, IDL cholesterol, and apoB concentrations were
strongly inversely correlated with LDL size in FCHL patients (Table 7). HDL
cholesterol concentration was positively correlated with LDL size. However, plasma
enzyme activities were not associated with LDL size in univariate analyses. Linear
regression analysis was used to identify independent associations between LDL size and
other variables. Age was first forced in the model, followed by lipid concentrations,
enzyme activities, and gender using the stepwise method. Although CETP and HL
activities were not correlated with LDL size in univariate analyses, they were
significantly associated with LDL size after the impact of serum triglyceride
concentration had been taken into account in the regression analysis (Table 8).
Table 7. Correlations between LDL particle size and serum lipoproteins, and lipoprotein
modifying enzyme activities in patients with FCHL (n=68) (Study I).
r p
Total triglycerides -0.71 <0.001
Total cholesterol -0.12 0.33
VLDL cholesterol -0.68 <0.001
IDL cholesterol -0.53 <0.001
LDL cholesterol 0.27 0.03
HDL cholesterol 0.52 <0.001
apo B -0.49 <0.001
HL activity -0.05 0.67
LPL activity -0.00 0.97
CETP activity -0.14 0.28
PLTP activity -0.06 0.63
6.2 Postprandial hyperlipidemia and LDL particle size
Effects of nateglinide and glibenclamide on postprandial glycemia and lipemia
Postprandial insulin secretion was significantly increased by nateglinide, and it was
associated with significant decreases in postprandial glucose and FFA concentrations
(Figure 8). Postprandial insulin secretion was significantly increased and postprandial
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glycemia decreased by glibenclamide, but the effect of glibenclamide on postprandial
FFA response was not significant (Figure 8). Neither nateglinide nor glibenclamide
affected fasting or postprandial triglyceride or apoB concentrations (Table 9 and Figure
9).
Table 8. Independent predictors of LDL size in multivariate stepwise linear regression
analysis (Study I).
All FCHL patients,
n=68
One FCHL patient from each pedigree,
n=34
Independent variable(s) Adjusted R2 Independent variable(s) Adjusted R2
Age 0.064 Age 0.114
Age, Tg 0.533 Age, Tg 0.501
Age, Tg, CETP 0.594 Age, Tg, HL 0.653
Age, Tg, CETP, HL 0.616
Age, Tg, CETP, HL, HDL-C 0.642
Table 9. Postprandial plasma triglycerides and apolipoproteins* (Study II).
Group Baseline On-trial
Total Tg, Nateglinide (n=23) 4.7±2.9 4.7±3.6
mmol⋅l-1⋅h Glibenclamide (n=20) 3.5±2.1 4.7±3.2
Chylomicron Tg, Nateglinide (n=23) 2.0±1.1 1.9±1.5
mmol⋅l-1⋅h Glibenclamide (n=20) 1.5±0.8 1.9±1.4
VLDL1 Tg, Nateglinide (n=23) 2.4±1.9 2.3±2.1
mmol⋅l-1⋅h Glibenclamide (n=18) 2.1±1.4 2.4±1.7
VLDL1 apoB 100, Nateglinide (n=23) 56±46 52±48
mg⋅dl-1⋅h Glibenclamide (n=18) 56±45 55±38
Chylomicron apoB 48, Nateglinide (n=23) 0.7±0.5 0.7±0.7
mg⋅dl-1⋅h Glibenclamide (n=20) 0.6±0.5 0.7±0.7
VLDL1 apoB 48, Nateglinide (n=23) 4.2±3.1 4.3±3.2
mg⋅dl-1⋅h Glibenclamide (n=18) 3.9±3.5 3.6±3.5
*Postprandial incremental AUC. Nateglinide and glibenclamide did not have significant
effect on postprandial lipoprotein responses.
Effect of postprandial hypertriglyceridemia on LDL particle size
LDL peak particle diameter did not significantly change during the 8-hour postprandial
period (25.47 ± 1.23 nm at fasting vs. 25.55 ± 1.19 nm at 8 hours). Fasting total (r= -
0.65, p<0.001) and VLDL1 triglyceride (r= -0.67, p<0.001) concentrations and
postprandial total (r= -0.65, p<0.001) and VLDL1 triglyceride (r= -0.69, p<0.001) AUC
values were strongly inversely correlated with LDL diameter.
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Figure 8. Baseline and on-trial serum insulin, glucose, and FFA
responses to fat-rich mixed meal.
6.3 LDL particle size, forearm endothelium-dependent vasodilation and insulin
sensitivity in healthy men
Endothelial function and insulin sensitivity
Blood flow responses to SNP and ACh infusions are shown in Figure 10. Basal forearm
blood flows were comparable in both groups. The endothelium-independent increase in
forearm blood flow induced by the SNP infusion was similar in both groups. The ACh-
induced endothelium-dependent increase in forearm blood flow was slightly diminished
among the men with small LDL particles during the low dose, and significantly
impaired during the high dose ACh infusion. The ratio between forearm blood flow
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Figure 9. Baseline and on-trial plasma lipid and lipoprotein
responses to fat-rich mixed meal.
during the high dose ACh to that during the high dose infusion of SNP was significantly
lower in men with small LDL particles (0.66 ± 0.29) than in those with large LDL
particles (1.18 ± 0.59, p=0.013). The ACh-induced fold-increase in blood flow above
basal was also significantly lower in men with small LDL particles (mean increase in
flow 266 ± 139 vs. 418 ± 160 %, men with small vs. large LDL particles, p=0.004),
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while SNP-induced fold-increases were similar in both groups (389 ± 161 vs. 424 ± 166
%, respectively, NS). Insulin-stimulated whole-body glucose uptake (M-value) was
significantly lower indicating attenuated insulin sensitivity in subjects with small LDL
particles (4.2 ± 1.3 vs. 5.9 ± 2.0 mg/kg body weight⋅minute, p=0.006).
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Figure 10. Left: SNP- and ACh-induced increases in forearm blood flow in men with
small LDL particles (squares) and in men with large LDL particles (circles).
Right: SNP- and ACh-induced increase in forearm blood flow in men with small LDL
particles (black) and in men with large LDL particles (white).
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Figure 11. Associations between LDL size, insulin sensitivity, HDL cholesterol and
triglyceride concentrations and maximal forearm blood flow response to ACh.
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Relationships between serum lipoproteins, insulin sensitivity, and endothelial function
ACh-induced increase in forearm blood flow was significantly correlated with LDL
particle size, but not with LDL cholesterol, HDL cholesterol, serum triglycerides, or
insulin sensitivity when all subjects were analysed together (Table 10, Figure 11). In
multivariate regression analysis with LDL particle size, LDL and HDL cholesterol,
serum triglycerides, age, systolic blood pressure, and insulin sensitivity index (M-value)
only LDL particle size was significantly associated with ACh-induced increase in
forearm blood flow (R2=0.204, p=0.010). When all the aforementioned variables were
forced in the model, the LDL particle size remained the only significant determinant of
ACh-induced increase in forearm blood flow (p=0.031). Insulin-stimulated whole-body
glucose uptake was significantly inversely correlated with BMI and serum triglyceride
concentration, and positively correlated with serum HDL cholesterol concentration
(Table 10). There was also a statistically nonsignificant trend for correlation between
insulin sensitivity and LDL particle size.
Table 10. Correlations between serum lipoproteins, insulin sensitivity, and endothelial
function in healthy men (Study III).
ACh-induced increase LDL peak particle M-value§
r p r p r p
LDL peak particle size 0.45 0.01 . . 0.30 0.09
M-value§ 0.21 0.25 0.30 0.09 . .
LDL cholesterol 0.22 0.22 -0.11 0.55 -0.22 0.21
HDL cholesterol 0.31 0.09 0.38 0.03 0.41 0.02
Total triglycerides -0.19 0.30 -0.44 0.01 -0.77 <0.001
Body mass index -0.21 0.24 -0.09 0.62 -0.41 0.02
§
 Insulin-stimulated whole-body glucose infusion rate.
6.4 LDL particle size and endothelial function in patients with type 2 diabetes
Endothelial function
Blood flow responses to SNP and ACh infusions are shown in Figure 12. SNP induced
similar endothelium-independent increase in forearm blood flow in both diabetic and
healthy men. In contrast, ACh-induced endothelium-dependent increase in blood flow
tended to be lower in diabetic men than in healthy men during the low-dose ACh
infusion (5.4 ± 2.9 vs. 6.7 ± 3.7 ml⋅dl-1⋅min-1) and it was significantly blunted during the
higher dose of ACh (5.4 ± 3.2 vs. 9.7 ± 5.1 ml⋅dl-1⋅min-1). When endothelial nitric oxide
generation was inhibited by simultaneous infusion of ACh and L-NMMA, the forearm
blood flow was similar in diabetic and healthy men. Thus, most of the difference in
ACh-induced blood flows between the groups was due to decreased bioavailability of
NO in diabetic men. The ratio of blood flows during high-dose ACh and high-dose SNP
was significantly lower in men with diabetes than in healthy men (Figure 12).
Relationships between serum lipoproteins and endothelial function
LDL particle size, but not glycemic control, blood pressure, serum lipoprotein
concentrations or plasma antioxidant parameters, was significantly correlated with
endothelial function measured as the ratio of blood flows during high-dose ACh and
high-dose SNP (r= -0.43, p<0.05) in diabetic men. Serum triglyceride concentration was
significantly inversely correlated with LDL particle size (r= -0.71, p<0.001).
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Figure 12. Forearm blood flow in experimental and control forearm in men with
type 2 diabetes (solid circles) and in healthy control men (open circles) during
infusions of SNP, ACh, and coinfusion of L-NMMA and ACh.
Insert: Ratio of forearm blood flows during high-dose infusion of ACh and SNP.
6.5 Fenofibrate treatment, LDL size and progression of coronary atherosclerosis in
subjects with type 2 diabetes
Effect of fenofibrate on plasma lipoproteins
Fenofibrate treatment significantly increased LDL particle size and HDL cholesterol
concentration and decreased plasma triglycerides, total cholesterol, LDL cholesterol,
and apoB concentrations compared with placebo (Table 11). The change in LDL size
was significantly associated with changes in plasma triglycerides (r= -0.56, p<0.0001),
HDL cholesterol (r= +0.34, p<0.0001), total cholesterol (r= -0.30, p<0.0001) and apoB
(r= -0.31, p<0.0001), as well as with the LDL cholesterol/apoB concentration ratio (r=
+0.29, p<0.0001).
Effects of plasma lipoproteins on progression of coronary atherosclerosis
In the combined group and in the fenofibrate group alone the greatest progression of
focal atherosclerosis (increase in percentage diameter stenosis and decrease in minimum
lumen diameter) and diffuse atherosclerosis (decrease in mean lumen diameter)
occurred in subjects with smallest on-treatment LDL particle size and highest plasma
apoB, total and LDL cholesterol, and triglyceride concentrations (Table 12). In the
placebo group on-treatment lipoproteins were not significantly associated with
angiographic changes.
Progression of focal coronary atherosclerosis (increase in percentage diameter stenosis)
in the combined group is illustrated in Figure 13. The 405 subjects were divided into
tertiles of mean on-treatment lipids and lipoproteins. The greatest deterioration was
predictably observed in patients with the highest LDL cholesterol, apoB, and
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triglyceride levels. Importantly, LDL size modulated the progression of CAD so that in
each tertile of LDL cholesterol, apoB, and triglyceride subjects with small LDL
particles had more progression of atherosclerosis than those with large LDL particles.
Again, the effect of LDL size and other lipoproteins was due to the fenofibrate group
alone and was not observed in the placebo group.
In multivariate regression analyses both on-treatment LDL cholesterol concentration
and final LDL particle size, as well as on-treatment apoB concentration and final LDL
particle size, significantly contributed to the progression of CAD in the combined group
(Table 13). Addition of triglyceride and HDL cholesterol did not significantly improve
the model, which is probably explained by the intercorrelations between these variables
and LDL size. These associations were due to the changes observed in the fenofibrate
group alone whereas no such associations were observed in the placebo group.
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Figure 13. Subjects divided into tertiles of mean on-treatment lipoproteins and final
LDL size. The greatest progression of coronary atherosclerosis was observed in
subjects with small LDL particles and highest LDL cholesterol, apoB, and triglyceride
levels (n=405, *n=399).
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tertile
LDL size tertileLDL size tertile
small
medium
large
small
medium
large
low
medium
high
low
medium
high
Table 13. Multivariate regression analysis of the change in percentage diameter stenosis in
total (n=405), fenofibrate (n=198), and placebo (n=207) groups.
Model R2
All
(n=405)
Fenofibrate
(n=198)
Placebo
(n=207)
LDL size and LDL-C 0.039*** 0.073*** 0.008
LDL size and apoB† 0.041*** 0.078*** 0.008
LDL size and HDL-C 0.026** 0.041* 0.016
LDL size and TG 0.027** 0.056** 0.007
LDL size, LDL-C, apoB, HDL-C, TG† 0.044** 0.082** 0.021
* p<0.05, **p<0.01, ***p<0.001.
†
 n =399 (All), n=196 (Fenofibrate), n=203 (Placebo).
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7. DISCUSSION
7.1 Evaluation of the methods
Gradient gel electrophoresis is a simple method to determine LDL subfraction
distribution. The measurement is highly reproducible with the coefficient of variation
approximately 1 to 2 % (43,195,196). The advantages of GGE include that LDL
particles do not need to be isolated by ultracentrifugation before the analysis and serum
samples can be used. In addition, storage at -80°C does not change LDL size. The most
important disadvantage of GGE is that the measurement of LDL subfraction lipid
concentrations is not possible. In the present studies LDL peak particle diameter was
used as the measure of LDL size. More data on the LDL distribution might have been
obtained by integrating the area under each LDL subclass peak (15,16,197).
Forearm blood flow response to intra-arterial infusion of ACh was used as the measure
of endothelial function in Studies III and IV. Clinically significant atherosclerosis in
forearm arteries is rare. However, in an autopsy study atherosclerotic lesions of the
brachial artery were significantly correlated with lesions in both coronary and carotid
arteries, which suggests that measurements performed in the forearm vascular bed may
provide important information regarding atherosclerosis in general (198). Consistent
with this, ACh-induced increases in both brachial and coronary artery blood flows are
attenuated in patients with mild coronary artery disease compared with subjects with
normal coronary angiograms (199). Moreover, forearm blood flow response to ACh
infusion is moderately related (r= 0.51, p=0.039, n=17) to ACh-induced constriction of
epicardial artery (200). In cross-sectional studies impaired endothelium-dependent
vasodilation has been found in forearm arteries in subjects with angiographically
verified coronary atherosclerosis as well as in those with risk factors for atherosclerosis,
such as hypercholesterolemia (109), type 1 and type 2 diabetes (176,201), and smoking
(202). Importantly, recent studies have identified impaired endothelium-dependent
vasodilation in both the forearm (203,204) and coronary (205-207) vascular beds as an
independent risk factor for coronary events. Limitations of this method include that it is
invasive and too elaborate to be used in clinical practice.
Progression of coronary artery atherosclerosis in Study V was determined by changes in
angiograms obtained at least three years apart. Angiography was chosen for several
reasons. It was considered that an angiographic approach would provide the fastest
answer to the hypothesis that correction of lipoprotein abnormalities in patients with
type 2 diabetes alters the course of CAD. A study with clinical endpoints would have
required substantially more patients and a longer follow-up time. The use of a
standardised angiographic approach allowed the examination of coronary arteries in
multiple centres. Obviously, angiography provides data only about luminal dimensions
and a large part of the development of atheromas in arterial wall cannot be measured
(137). The use of a more sophisticated method, such as intravascular ultrasound, would
have allowed visualisation of the atheroma in addition to the lumen diameter and
provided substantially more information on the progression of coronary atherosclerosis
(139). However, at the time when the Diabetes Atherosclerosis Intervention Study was
designed the standard method for determination of coronary atherosclerosis was
angiogram. Due to the potential inaccuracy of angiogram the observed associations
between lipoproteins and CAD progression may underestimate the true associations
between them.
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7.2 Effects of triglycerides, CETP, and HL on LDL particle size
In all the studies fasting triglyceride concentration was strongly and inversely correlated
with LDL peak particle size. Moreover, in Study V the change in plasma triglyceride
concentration during follow-up was strongly and inversely correlated with the change in
LDL diameter. The results emphasise the importance of serum triglyceride
concentration as the most important regulator of LDL particle size. The data are in
accordance with previous findings (15,16,41-43).
One of the features of familial combined hyperlipidemia is preponderance of small,
dense LDL particles. However, the relative contributions of genetic and non-genetic
factors on the variation in LDL size in FCHL are still debated (75,85,208). LDL size has
been linked to HL gene locus and CETP/LCAT gene locus in Dutch FCHL families
(36,209). The associations between serum triglyceride concentration and HL, LPL,
CETP, and PLTP activities and LDL particle size were evaluated in Study I. A strong
inverse correlation was found between serum triglycerides and LDL size in FCHL
patients. Although CETP and HL activities did not correlate with LDL size in univariate
analyses, they were significantly associated with LDL size in the multivariate regression
analysis, i.e. when the influence of triglycerides was accounted for. The data suggest
that serum triglyceride concentration is the most important determinant of LDL particle
size also in patients with FCHL, and that CETP and HL activities modify LDL
phenotype to a lesser amount. Two relatively small studies have evaluated whether
lowering serum triglyceride concentration by gemfibrozil changes LDL particle size and
density in patients with FCHL (87,88). Although triglyceride concentration decreased
significantly in both studies it remained relatively high (1.9 ± 0.9 and 1.4 ± 0.4 mmol/l,
respectively). Fasting serum triglyceride concentration 1.5 to 1.7 mmol/l has been
suggested for a threshold for preponderance of small, dense LDL particles (44,210). A
large proportion of FCHL patients in the two aforementioned studies had triglyceride
concentrations above that level even though they were treated with gemfibrozil, which
may in part explain why the majority of their LDL subfraction profile remained small
and dense.
The effect of short-term postprandial hypertriglyceridemia on LDL peak particle
diameter was evaluated in Study II. Both nateglinide and glibenclamide augmented
postprandial insulin secretion and attenuated hyperglycemia confirming the results of a
previous study (211). In contrast to the hypoglycemic effect and unlike the hypothesis,
augmented postprandial insulin secretion did not decrease concentrations of
postprandial endogenous and exogenous triglyceride-rich lipoproteins. These data
support and extend the finding of Malmström et al. who reported that the inhibitory
effect of insulin on the hepatic VLDL1 production in fasting conditions is impaired in
subjects with type 2 diabetes (5). It appears that disruptions in hepatic insulin signalling
pathways may be crucial in the hepatic VLDL1 overproduction in type 2 diabetes, and
that oral insulinotropic agents cannot provide sufficient hyperinsulinemia to override
this impairment. The specific defects in the insulin signalling pathway cannot be
determined from the results of our study. The results of the study have clinical
relevance. In western countries people often consume meals and snacks no more than
three to four hours apart, and postprandial period is in fact the typical state of being.
Especially in subjects with tendency for prolonged postprandial hyperlipidemia, like
diabetic patients, this leads to cumulative hyperlipidemia during the day (212). A close
inverse correlation was found between fasting triglycerides and postprandial triglyceride
AUC and LDL particle size, but only a modest correlation between the incremental
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triglyceride AUC and LDL size. No significant change in LDL size during the 8-hour
postprandial hypertriglyceridemia was detected. These data emphasise the importance
of chronic hypertriglyceridemia as a crucial factor in the formation of small, dense LDL
particles and suggest that short-term changes in triglyceride concentration are not
sufficient to allow LDL modulation. Supporting our findings, Attia et al. have also
reported that the dominant LDL subfraction (reflecting LDL peak particle size) does not
change during postprandial hypertriglyceridemia, although minor changes in the relative
proportions of dense, intermediate and buoyant LDL may occur (213).
7.3 LDL particle size, insulin sensitivity and endothelial function in healthy men
Men with low whole-body insulin-stimulated glucose uptake had higher serum
triglyceride concentration than men with high glucose uptake. Insulin sensitivity and
LDL particle size were not significantly associated, but serum triglyceride concentration
was strongly inversely correlated with LDL size. These results, consistent with previous
data (43,63-67), imply that insulin resistance causes hypertriglyceridemia and the
decrease in LDL size is due to the metabolic effects induced by serum triglycerides.
Men with small LDL particles had an impaired response to endothelium-dependent
vasodilator ACh compared with men with similar LDL cholesterol concentration and
large LDL particles. Moreover, when all subjects were analysed together LDL particle
size was the only variable significantly associated with the blood flow response to ACh.
Because endothelial dysfunction is an early indicator of vascular damage these data
suggest, although not prove, that small LDL particles may mediate at least a part of the
adverse vascular consequences of insulin resistance. Limitations of the study include the
relatively small number of subjects. In addition, the effects of low HDL cholesterol
concentration and hypertriglyceridemia on endothelial function cannot be entirely
excluded even though they did not have statistically significant effect.
7.4 LDL particle size, endothelial function and progression of coronary
atherosclerosis in patients with type 2 diabetes
Patients with type 2 diabetes had an impaired response to endothelium-dependent
vasodilator ACh and a normal response to endothelium-independent vasodilator SNP.
During coinfusion of L-NMMA with ACh, which abolished the NO-dependent
component of ACh action, the diabetic patients and the normal subjects had similar
blood flow responses. This implies that defective NO production or increased NO
destruction mediates endothelial dysfunction in type 2 diabetes. The patients were
characterised by relatively short duration of disease, they had no signs of macrovascular
complications, and they had similar sympathetic vasomotoric function as healthy
control men. Endothelial dysfunction in type 2 diabetic patients with varying
complications has been found in several studies (201,214-224). These studies document
that endothelial dysfunction is a common, if not uniform, feature in patients with type 2
diabetes. Regarding data on endothelium-independent vasodilatory response to direct
NO donors in subjects with type 2 diabetes, the response has been either similar
(201,219,221,222,225-228) or impaired (214,216,223,229-231) compared with normal
subjects. Different characteristics of the diabetic patients (e.g. glycemic control and
dyslipidemia, duration of diabetes, absence or presence of autonomic neuropathy), poor
matching of diabetic patients and control groups and differences in the methodology and
the vessels studied could provide explanation to the variation in the endothelium-
independent vascular function.
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LDL particle size was the only metabolic parameter that was significantly associated
with endothelial function in men with type 2 diabetes. The association between LDL
size and endothelial function in diabetic patients has also been reported by others
(218,220). McNeill et al. have found that LDL particles obtained from patients with
type 2 diabetes impair vasorelaxation to ACh in vitro more than LDL particles from
nondiabetic subjects (221). They did not find association between LDL size and
response to ACh, however, and suggested that unidentified qualitative properties of
LDL may account for the endothelial dysfunction in type 2 diabetes. Interestingly,
statins have failed to improve endothelium-dependent vasodilation in three studies in
patients with type 2 diabetes (222-224), and in two other studies the improvement was
associated with markers of inflammation or NO bioavailability but not with serum lipids
(229,232). In clinical studies use of statins has decreased cardiovascular morbidity and
mortality in patients with type 2 diabetes (233,234), but it is at present unclear to what
extent serum cholesterol lowering vs. other effects of statins (235) contribute to this
benefit. Poor glycemic control is associated with endothelial dysfunction in type 1
diabetes (176), possibly due to increased oxidative stress related to hyperglycemia
(236). The lack of association between glycemic control and endothelial function in
type 2 diabetes found by us in Study IV and previously by others (214,216,217) may be
due to coexistence of dyslipidemia, hypertension, or other metabolic abnormalities
which confound the relationship between hyperglycemia and endothelial function.
Although both small LDL size and high HbA1c were associated with increased
susceptibility of LDL to oxidation in vitro, susceptibility of LDL to oxidation was not
associated with endothelial function. It should be noted, however, that it is not known
how reliably the Cu++ induced oxidation in vitro reflects the oxidation processes in
vascular wall (237).
LDL particle size as well as apoB, LDL and total cholesterol and triglyceride
concentrations were associated with all three angiographic parameters that measured the
progression of coronary atherosclerosis in Study V. Moreover, LDL particle size had a
combined effect with LDL cholesterol and apoB concentrations on the progression of
coronary atherosclerosis. These data imply that both quality and quantity of LDL
particles are important factors when evaluating the risk of coronary artery disease.
However, more than 90 % of the variation in measured atherosclerosis progression was
not accounted for by plasma lipoproteins. At least two possible explanations may
account for this weak association. First, it is possible that factors such as local
inflammatory reaction and activity of reverse cholesterol transport are more important
in atherosclerosis progression than measured lipoprotein concentrations or LDL size
(238-242). Second, as discussed in chapter 7.1, because of potential inaccuracies of
angiography observed associations between lipoproteins and progression of CAD may
underestimate actual associations between them. In previous angiographic trials
(92,161,243) serum lipoprotein concentrations have explained a similar degree of
variation in the progression of CAD as in Study V. In the majority of prospective trials
small LDL particle size has increased the risk of a future coronary artery disease,
although its predictive value has been weaker after adjustment for other lipid risk
factors (153-156). In contrast, Campos et al. have reported that large LDL particles
increase the risk of recurrent coronary event in the placebo group of the Cholesterol and
Recurrent Events (CARE) trial (160). Their results are in conflict with the
aforementioned studies (153-156). There is no obvious explanation for these conflicting
data. The most striking difference between the studies is that the participants in the
CARE trial were survivors of myocardial infarction, but in the other trials (153-156)
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they were free of known cardiovascular disease at baseline. A better predictor of
cardiovascular risk has been obtained when data on LDL peak particle size (157) or
LDL particle size distribution (158) have been combined with the data on LDL
cholesterol concentration or other dyslipidemias. Results of Study V support the view
that small LDL particles are more atherogenic than mid-sized and large LDL and
emphasise the importance of multiple risk factors in prediction of CAD risk.
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8. SUMMARY AND CONCLUSIONS
1. Serum triglyceride concentration has a close inverse association with LDL particle
size. CETP and HL activities have a smaller effect on LDL size. Therefore,
decreasing serum triglyceride concentration is the most efficient way to increase
LDL size.
2. Insulinotropic agents nateglinide and glibenclamide do not significantly affect
fasting or postprandial plasma lipid concentrations although they attenuate
hyperglycemia in type 2 diabetic patients. This implies that the inhibitory effect of
insulin on hepatic VLDL1 production is impaired in subjects with type 2 diabetes.
3. Small LDL particle size is associated with impaired endothelium-dependent
vasodilation in healthy men and in men with type 2 diabetes. In contrast, LDL
susceptibility to oxidation in vitro and plasma antioxidant concentrations are not
associated with endothelium-dependent vasodilation in men with type 2 diabetes.
4. Men with small LDL particles have attenuated insulin-stimulated whole-body
glucose uptake. The association between insulin sensitivity and LDL size is not
direct, however, but mediated by serum triglyceride concentration.
5. LDL particle size and plasma lipid and lipoprotein concentrations have a combined
effect on the progression of coronary atherosclerosis in patients with type 2 diabetes.
Cardiovascular disease is a major cause of morbidity and mortality in the westernised
world. Our results confirm that serum triglyceride concentration is the strongest
determinant of LDL particle size and show that measuring LDL particle size gives
additional information on the presence and progression of atherosclerosis. The methods
used in the current studies are, however, too elaborate to be used in clinical settings in
order to evaluate the risk of cardiovascular disease in an individual patient.
Identification of novel predictors of cardiovascular disease remains an important
challenge.
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